Nxera Pharma repurchases 2028 euroyen convertible bonds

Nxera Pharma announced the results of its repurchase of the 2028 euroyen-denominated convertible bonds with stock acquisition rights (the "Existing Bonds") on December 22, 2025. The repurchase was executed on December 19, 2025, following a resolution by the Board of Directors on November 26, 2025.

The total repurchase price for the bonds amounted to JPY 4,837.5 million, representing a total face value of JPY 5,000 million. This price reflects JPY 9,675,000 per JPY 10 million face value, excluding accrued interest, which will be paid separately. After this transaction, the remaining face value of the outstanding bonds is JPY 27 million.

The company is currently assessing the impact of this repurchase on its consolidated financial performance for the fiscal year ending December 2025, including financial gains or losses. Any material developments regarding this impact will be disclosed promptly.